Page 35 - 2021_02-Haematologica-web

Inherited platelet function disorders
20. Takagi J, Petre BM, Walz T, Springer TA. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell. 2002;110(5): 599-611.
21. Zhu J, Zhu J, Springer TA. Complete integrin headpiece opening in eight steps. J Cell Biol. 2013;201(7):1053-1068.
22. Guillet B, Bayart S, Pillois X, Nurden P, Caen JP, Nurden AT. A Glanzmann thrombasthe- nia family associated with a TUBB1-related macrothrombasthenia. J Thromb Haemost. 2019;17(12):2211-2215.
23. Jamasbi J, Ayabe K, Goto S, Nieswandt B, Peter K, Siess W. Platelet receptors as thera- peutic targets: past, present and future. Thromb Haemost. 2017;117(7):1249-1257.
24. Roule V, Agueznai M, Sabatier R, et al. Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syn- dromes: a meta-analysis of pivotal trials. Platelets. 2017;28(2):174-181.
25. Canault M, Ghalloussi D, Grosdidier C, et al. Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe bleeding. J Exp Med. 2014;211(7): 1349-1362.
26. Canault M, Alessi MC. RASGRP2 structure, function and genetic variants in platelet pathophysiology. Int J Molec Sci. 2020; 21(3):1075.
27. Stefanini L, Bergmeier W. RAP GTPAses and platelet integrin signaling. Platelets. 2019;30(1):41-47.
28.Desai A, Bergmeier W, Canault M, et al. Phenotype analysis and clinical manage- ment in a large family with a novel truncat- ing mutation in RASGRP2, the CalDAG- GEFI encoding gene. Res Pract Thromb Haemost. 2017;1(1):128-133.
29. Rognoni E, Ruppert R, Fassler R. The kindlin family: functions, signaling properties and implications in disease. J Cell Sci. 2016;129 (1):17-27.
30. Jurk K, Schulz AS, Kehrel BE, et al. Novel- integrin dependent platelet malfunction in siblings with leukocyte adhesion deficiency- III (LAD-III) caused by a point mutation in FERMT3. Thromb Haemost 2010;103(5): 1053-1054.
31. Nagy M, Mastenbroek TG, Mattheij NJA, et al. Variable impairment of platelet functions in patients with severe genetically linked immune deficiencies. Haematologica. 2018;103(3):540-549.
32. Moser M, Nieswandt B, Ussar S, Pozgajova M, Fassler R. Kindlin-3 is an essential cofac- tor for integrin activation and platelet aggre- gation. Nat Med. 2008;14(3):325-330.
33. Kuijpers T.W, van de Vijver E, Weterman MA et al. LAD-1/variant syndrome is caused by mutations in FERMT3. Blood. 2009;113(19):4740-4746.
34. Malinin NL, Plow EF, Byzova TV. Kindlins in FERM adhesion. Blood. 2010;115(20):4011- 4017.
35.Weiss HJ. Scott syndrome: a disorder of platelet coagulant activity. Semin Hematol. 1994;31(4):312-319.
36.Suzuki J, Umeda M, Sims PJ, Nagata S. Calcium-dependent phospholipid scram- bling by TMEM16F. Nature. 2010;458(7325): 834-838.
37.Toti F, Satta N, Fressinaud E, Meyer D, Freyssinet JM. Scott syndrome characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hem- orrhagic complications, is an inherited disor- der. Blood. 1996;87(4):1409-1415.
38. Lhermusier T, Chap H, Payrastre B. Platelet
39.
membrane phospholipid asymmetry: from the characterization of a scramblase activity to the identification of an essential protein mutated in Scott syndrome. J Thromb Haemost. 2011;9(10):1883-1891. Millington-Burgess SL, Harper MT. Gene of the issue: ANO6 and Scott syndrome. Platelets. 2020;31(7):964-967
55. Reyes J, Watson SP, Nieswandt B. Functional significance of the platelet immune recep- tors CLEC-2 and GPVI. J Clin Invest. 2019;129(1):12-23.
56. Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glyco- protein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest. 1989;84(5):1440-1445.
57. Nurden AT. Clinical significance of altered platelet collagen-receptor functioning in platelets with emphasis on glycoprotein VI. Blood Rev. 2019;38:100592.
58. Jandrot-Perrus M, Hermans C, Mezzano D. Platelet glycoprotein VI genetic quantitative and qualitative defects. Platelets. 2019;30(6):708-713.
59. Matus V, Valenzuela G, Saez CG, et al. An adenine insertion in exon 6 of human GP6 generates a truncated protein associated with a bleeding disorder in four Chilean families. J Thromb Haemost. 2013;11(9): 1751-1759.
60. Nisar SP, Jones ML, Cunningham MR, Mumford AD, Mundell SJ, on behalf of the UK GAPP study group. Rare platelet GPCR variants: what can we learn? Br J Pharmacol. 2015;172(13):3242-3253.
61. Habib, A, FitzGerald, GA, Maclouf, J. Phosphorylation of the thromboxane recep- tor alpha, the predominant isoform expressed in human platelets. J Biol Chem. 1999;274(5):2645–265.
62.Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, Narumiya S. Arg60 to Leu muta- tion of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder J Clin Invest. 1994;94(4):1662-1667.
63. Fuse I, Hattori A, Mito M, et al. Pathogenetic analysis of five cases with a platelet disorder characterized by the absence of thrombox- ane A2 (TXA2)-induced platelet aggregation in spite of normal TXA2 binding activity. Thromb Haemost. 1996;76(6):1080-1085.
64. Mundell SJ, Mumford A. TBXA2R gene vari- ants associated with bleeding. Platelets. 2018;29(7):739-742.
65. Lebozec K, Jandrot-Perrus M, Avenard G, Favre-Bulle O, Billiald P. Design, develop- ment and characterization of ACT017, a humanized Fab that blocks platelet’s glyco- protein VI function without causing bleed- ing risks. MAbs. 2017;9(6):945-958.
66. Mammadova-Bach E, Gil-Pulido J, Sarukhanyan E, et al. Platelet glycoprotein VI promotes metastasis through interaction with cancer cell-derived galectin-3. Blood. 2020;135(14):1146-1160.
67. Huizing M, Helip-Wooley A, Westbrook W, Gunay-Aygun M, Gahl WA. Disorders of lysosome-related organelle biogenesis: clini- cal and molecular genetics. Ann Rev Genomics Hum Genet. 2008;9:359-386.
68. Bowman SL, Bi-Karchin J, Le L, Marks MS. The road to lysosome-related organelles: insights from Hermansky-Pudlak syndrome and other rare diseases. Traffic. 2019;20(6): 404-435.
69. Ambrosio AL, Di Pietro SM. Storage pool diseases illuminate platelet dense granule biogenesis. Platelets. 2017;28(2):138-146.
70. Huizing M, Malicdan MCV, Wang JA, et al. Hermansky-Pudlak syndrome: mutation update. Hum Mutat. 2020;42(3):543-580.
71. Karampini E, Bierings R, Voorberg J. Orchestration of primary hemostasis by platelet and endothelial lysosome-related organelles. Arterioscler Thromb Vasc Biol. 2020;40(6):1441-1453.
72. Enders A, Zieger B, Schwartz K, et al Lethal hemophagocytic lymphohistiocytosis in
40. Reddy EC, Rand ML. Procoagulant phos- phatidylserine-exposing platelets in vitro and in vivo. Front Cardiovasc Med. 2020;7:15.
41. Boisseau P, Bene MC, Besnard T, et al. A new mutation of ANO6 in two familial cases of Scott syndrome. Br J Haematol. 2018;180(5):750-752.
42. Castoldi E, Collins PW, Williamson PL, Bevers EM. Compound heterozygosity for 2 novel TMEM16F mutations in a patient with Scott syndrome. Blood. 2011;117(16): 4399-4400.
43. Berrou E, Soukaseum C, Favier R, et al. A mutation of the human EPHB2 gene leads to a major platelet functional defect. Blood. 2018;132(19):2067-2077.
44. Cattaneo M. The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood. 2011;117(7): 2102-2012.
45. Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new congenital detect of platelet func- tion characterized by severe impairment of platelet responses to adenosine diphos- phate. Blood. 1992;80(11):2787-2796.
46. Nurden P, Savi P, Heilmann E, et al. An inher- ited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb– IIIa complex function. J Clin Invest. 1995;95(4):1612-1622.
47. Mundell SJ, Rabbolini D, Gabrielli S, et al. Receptor homodimerization plays a critical role in a novel dominant negative P2RY12 variant identified in a family with severe bleeding. J Thromb Haemost. 2018;16(1):44- 53.
48.Lecchi A, Femia EA, Paoletta S, et al. Inherited dysfunctional platelet P2Y12 receptor mutations associated with bleeding disorders. Hamostaseologie. 2016;36(4):279- 283.
49. Cattaneo M, Zighetti ML, Lombardi R, et al. Molecular bases of defective signal transduc- tion in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci U S A. 2003;100(4):1978-1983.
50. Zhang K, Zhang J, Gao ZG, et al. Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature. 2014;509(7498):115-118.
51. Nisar S, Daly ME, Federici AB, et al. An intact PDZ motif is essential for correct P2Y12 purinoceptor traffic in human platelets. Blood. 2011;118(20):5641-5651.
52. Patel YM, Lordkipanidze M, Lowe GC, et al. A novel mutation in the P2Y12 receptor and a function-reducing polymorphism in pro- tease-activated receptor 1 in a patient with chronic bleeding. J Thromb Haemost. 2014;12(5):716-725.
53. Daly ME, Dawood BB, Lester WA, et al. Identification and characterization of a novel P2Y12 variant in a patient diagnosed with type I von Willebrand disease in the European MCMDM-1VWD study Blood. 2009;113(17):4110-4113.
54. Mammadova-Bach E, Ollivier V, Loyau S, et al. Platelet glycoprotein VI binds to polymer- ized fibrin and promotes thrombin genera- tion. Blood. 2015;126():683-691.
haematologica | 2021; 106(2)
349